Core Insights - Akero Therapeutics announced new findings from the SYMMETRY and HARMONY Phase 2b trials of efruxifermin, indicating its potential to reduce disease progression risk in compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH) [1][2][5] - The results will be presented at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 [1] Trial Findings - Post-hoc analyses from the 96-week SYMMETRY trial reinforce the antifibrotic activity of efruxifermin in patients with F4c MASH [2][5] - AI-powered digital pathology analysis corroborated fibrosis improvements observed in the HARMONY trial, supporting the efficacy of efruxifermin [3][5] Presentation Details - Oral presentations will include findings on improvements in non-invasive tests indicative of fibrosis regression and markers of portal hypertension in compensated cirrhosis due to MASH [3][6] - Poster presentations will focus on quantitative digital pathology results and AI-driven changes in liver microarchitecture in participants with F2/F3 MASH [6] Company Overview - Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases, including MASH [7] - Efruxifermin is currently being evaluated in three ongoing Phase 3 clinical trials, building on the results from the SYMMETRY and HARMONY Phase 2b trials [7]